Elitek (Rasburicase) - Summary

ELITEK SUMMARY

ELITEK (rasburicase) is a recombinant urate-oxidase enzyme produced by a genetically modified Saccharomyces cerevisiae strain. The cDNA coding for rasburicase was cloned from a strain of Aspergillus flavus.

ELITEK (rasburicase) is indicated for the initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.

ELITEK NEWS HIGHLIGHTS

Published Studies Related to Elitek (Rasburicase)

A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. [2001.05.15]

Effective treatment and prophylaxis of hyperuricemia and impaired renal function in tumor lysis syndrome with low doses of rasburicase. [2008.04]

Acute tumor lysis syndrome during oral fludarabine treatment for chronic lymphocytic leukemia. Role of treatment with rasburicase. [2008.04]

SFCE (Societe Francaise de Lutte contre les Cancers et Leucemies de l'Enfant et de l'Adolescent) recommendations for the management of tumor lysis syndrome (TLS) with rasburicase: an observational survey. [2008.04]

Rasburicase in the prevention and treatment of tumour lysis syndrome. [2008.02]

more>>

Clinical Trials Related to Elitek (Rasburicase)

Rasburicase as a Uricolytic Therapy for Hyperuricemia in Patients With Leukemia or Lymphoma [Completed]

Rasburicase for Hyperuricemia [Completed]

Rasburicase for the Treatment/Prevention of Hyperuricemia in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma [Terminated]

Fasturtec TLS Treatment / Prophylysis [Completed]

Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS [Completed]

more>>